CTI BioPharma Corp is a biopharmaceutical company in the USA . The main objective of the company is the creation of low-toxic and effective anti-cancer drugs, primarily new drugs against blood cancer [2] .
| CTI BioPharma Corp | |
|---|---|
 | |
| Type of | Public company |
| Listing on the exchange | |
| Base | 2014 |
| Former names | Cell Therapeutics Inc. |
| Location |  USA |
| Industry | Healthcare, biopharmaceuticals |
| Products | Pixuvri |
| Net profit | β² $ 4.27 million ( 2016 ) |
| Capitalization | $ 135.53 million (as of February 2017) [1] |
| Number of employees | 149 (as of February 2017) |
| Site | ctibiopharma.com |
Content
Current clinical trials
As of February 2017, the company has two drugs under development. The drug Pacritinib is in the 3rd stage of clinical trials. The drug inhibits the action of tyrosine kinase (ITC) [3]
Products
PIXUVRI (Pixantrone) - is used as monotherapy in the treatment of adult patients with repeatedly recurring or aggressive non-Hodgkin lymphoma . The drug was granted conditional permission to sell in the EU. PIXUVRI is not approved in the USA [4] .
Notes
- β CTI BioPharma Corp. Google Finance . The appeal date is February 2, 2017.
- β MarketMovers - CTI BioPharma Corp (NASDAQ: CTIC) , MarketMovers , February 2, 2017.
- β CTI BioPharma Corp Pipeline , CTI BioPharma Corp , February 2, 2017.
- β PIXUVRI - CTI , CTI BioPharma , February 2, 2017.
Links
- Official site of the company (English)
,,